This site is intended for healthcare professionals
Drug News

Health Canada approves Rinvoq for treatment of rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate (MTX).- AbbVie

Read time: 1 mins
Published:9th Jan 2020
AbbVie announced that Health Canada has approved Rinvoq (upadacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (MTX). Rinvoq is a 15 mg, once-daily oral Janus kinase (JAK) inhibitor and may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying anti-rheumatic drugs (DMARDs). AbbVie said the approval from Health Canada was supported by efficacy and safety data from the pivotal Phase III SELECT rheumatoid arthritis program which evaluated nearly 4,400 patients with moderate to severe active rheumatoid arthritis in five pivotal studies. Designed to help accommodate the physical limitations of people living with RA, the packaging for Rinvoq includes a bottle cap with a wide, easy-to-grip texture and an embedded tool that punctures the foil liner to simplify medication access.
Condition: Rheumatoid Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.